Benzinga | Jul 16, 2021 08:04AM EDT

Fate Therapeutics Highlights Will Host Virtual Event On Interim Phase 1 Trial Data From Its Off-The-Shelf NK Cell Franchise For B-Cell Lymphoma

Fate Therapeutics, Inc. (NASDAQ:FATE), a clinical-stage biopharmaceutical company dedicated to the development of programmed cellular immunotherapies for cancer, today announced that management will host a virtual event to highlight interim Phase 1 clinical data from its FT596 and FT516 programs for the treatment of relapsed / refractory B-cell lymphomas on August 19, 2021 at 4:30 p.m. ET.

The live webcast of the presentation can be accessed under "Events & Presentations" in the Investors section of the Company's website at www.fatetherapeutics.com. The archived webcast will be available on the Company's website beginning approximately two hours after the event.